Oxford, UK – 04 April 2022. OGT, A Sysmex Group Company, announces the appointment of Adrian Smith as CEO from 1st April 2022. The appointment comes as Dr John Anson retires from his position as CEO and member of the Board, after more than 16 years with the company.
Smith is a highly experienced, successful and well-regarded business leader in the life science and in-vitro diagnostics field. Both OGT and its parent company Sysmex Corporation are united in the conviction that he is an ideal fit for the next stage of OGT’s growth. Smith joins the company from breakthrough diagnostic and medical imaging solutions company, Hologic, where he was General Manager of the UK and Ireland. Prior to this he held leadership positions in Qiagen and Roche —both leading diagnostic companies—and brings a wealth of sector experience.
Under the decisive leadership of Anson, OGT made great strides in developing its molecular diagnostics portfolio of CytoCell® FISH probes, CytoSure® microarray and NGS products and SureSeq™ NGS panels. He commented, “It has been a pleasure and an honour to serve at OGT for the past 16 years. This is a company truly devoted to its customers with a unique and dedicated team that go above and beyond every day. I know this is an ethos that Adrian strongly shares and I can’t think of a better person to take OGT forward.”
As CEO, Smith will now lead the company in its next chapter as OGT looks to reinforce, develop, and grow its mission to improve clinical care by partnering with its customers. OGT’s support, expertise and comprehensive range of genomic solutions are already highly regarded, with the focus now on expanding the portfolio and increasing the accessibility to these worldwide.
Smith commented “I’m excited to join OGT at this moment in the company’s development. John has done a fantastic job steering this team – it’s rare to come across a company so passionate and dedicated to partnering with its customers to improve clinical care. I am dedicated to continuing John’s legacy by leveraging my drive, enthusiasm and experience to help continue to guide this exceptional team in this mission and through this next exciting phase of organic and inorganic growth.”
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell, CytoSure and SureSeq ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
CytoSure, SureSeq and myProbes: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the Prime Market of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
State-of-the-art premises increases operational footprint and will host Sysmex global R&D facility.Read
Sysmex demonstrates confidence and investment in OGT and the United Kingdom.Read
On 1st April 2018 Dr John Anson took over as CEO from Dr Mike Evans, who has become a non-executive director of OGT’s board.Read